ReviewClinical and experimental medicine2026
"Cytokine-Mediated tumor sensitization: mechanistic frameworks and therapeutic opportunities in cancer Immunotherapy".
Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cancer Cachexia Research and Drug Development: Lessons from Failures and the Promise of Immunomodulation.Cancers · 2026Review
- Research trends in cytokine regulation of immunotherapy in non-small cell lung cancer: a bibliometric and BERTopic analysis from 2015 to 2025.Journal of thoracic disease · 2026Article
- Cross-layer multiomic and digital pathology analysis identifies a malignant keratinization state linked to immune exclusion in cervical squamous carcinoma.Journal of translational medicine · 2026Article
- Dual-block HER2 assessment reveals clinically relevant intratumoral heterogeneity in gynecologic cancers: a single-center landscape analysis.Journal of translational medicine · 2026Article
- Enhancing the positive predictive value of early-stage ovarian cancer detection using a two-step machine learning framework.Journal of translational medicine · 2026Article
- In vitro cytotoxic and apoptotic effects of chitosan-coated gold nanoparticles on HT-29 human colorectal adenocarcinoma cells.BMC gastroenterology · 2026Article
- Late-stage dedifferentiation and epigenetic memory of cancer stem cells in hepatocellular carcinoma.Journal of translational medicine · 2026Article
- Spatial architecture of the melanoma immune niche reveals CORO1A as a functional hub for T cell cytotoxicity and immunotherapy synergy.Journal of translational medicine · 2026Article
- Review
- Genetic Variants of BMI1 (rs1042059 and rs11591377) and Their Potential Role in Leukemia Susceptibility: A Narrative Review.Health science reports · 2026Article
- Influence of poly(styrene-co-maleic anhydride) molecular weight on nanoparticle-mediated drug delivery in breast cancer.Journal of translational medicine · 2026Article
- Mitophagy in bladder cancer: a double-edged sword in tumor progression and therapy.Journal of translational medicine · 2026Review
- Differential Cytokine Profiles in Prostate Cancer Under Treatment: Implications for Prognosis and Synergistic Therapy Design.Cancers · 2026Article
- Soluble cytokines and chemokines in NSCLC: drivers of immune evasion and angiogenesis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokines are pivotal regulators of immune responses and inflammation, and their dysregulation is implicated in cancer initiation and progression. A deeper understanding of cytokine-mediated modulation of tumor cell behavior may uncover novel therapeutic targets for cancer treatment.A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science databases using keywords such as "cytokines," "tumor sensitization," "immune regulation," and "cancer therapy." Peer-reviewed articles published between 2002 and 2025 were evaluated and synthesized to provide an updated overview of cytokine-related therapeutic strategies.This review highlights the complex roles of key cytokines-including interleukins (IL-1, IL-6, IL-8, IL-10, IL-17), interferons (types I and II), tumor necrosis factor-α (TNF-α), and transforming growth factor-β (TGF-β)-in modulating tumor cell susceptibility to therapeutic interventions. While cytokines exhibit both tumor-promoting and tumor-suppressive properties, recent advances in cytokine engineering, targeted delivery systems, and combination immunotherapies have enhanced their clinical potential.Integrating cytokine modulation into oncology may improve personalized immunotherapy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.